David M. Mott made five open market purchases of Ardelyx, Inc. (ARDX) shares over the last year, totaling $5.35 million. His most recent buy occurred on February 20, 2026. These purchases rank 158th among 4,983 individual insiders, surpassing the average buy amount of $1.46 million across 3.29 transactions. Mott reported no open market sales in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 20, 2026 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Not found | P | Common Stock | 333333 | $5.84 | 3,302,918.0000 | 245,247,427 | 11.22% | 0.14% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | U | Common Stock | 383 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | U | Common Stock | 23546 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.47% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 264 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 368 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 788 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.02% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 1000 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.02% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 1011 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.02% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 400 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 2460 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.05% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 2200 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.04% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 734 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 1800 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.04% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 740 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 1002 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.02% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | D | Stock Option (right to buy) | 181 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.00% |
| June 20, 2025 | NOVAVAX INC | $NVAX | MOTT DAVID M | Director | A | Restricted Stock Units | 18884 | $0.00 | 18,884.0000 | 152,190,000 | 9999.99% | 0.01% |
| June 20, 2025 | NOVAVAX INC | $NVAX | MOTT DAVID M | Director | A | Stock Option (Right to Buy) | 28326 | $6.42 | 28,326.0000 | 152,190,000 | 9999.99% | 0.02% |
| June 18, 2025 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | A | Stock Option (Right to Buy) | 54059 | $0.00 | 54,059.0000 | 238,356,222 | 9999.99% | 0.02% |
| June 18, 2025 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | A | Common Stock | 31163 | $0.00 | 2,928,034.0000 | 238,356,222 | 1.08% | 0.01% |
| June 18, 2025 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | A | Common Stock | 41551 | $0.00 | 2,969,585.0000 | 238,356,222 | 1.42% | 0.02% |
| June 16, 2025 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | P | Common Stock | 200000 | $3.63 | 2,896,871.0000 | 238,356,222 | 7.42% | 0.08% |
| June 12, 2025 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | A | Stock Option (right to buy) | 61500 | $0.00 | 61,500.0000 | 124,631,339 | 9999.99% | 0.05% |
| June 12, 2025 | NOVAVAX INC | $NVAX | MOTT DAVID M | Not found | M | Common Stock | 10420 | $0.00 | 60,890.0000 | 152,190,000 | 20.65% | 0.01% |
| June 12, 2025 | NOVAVAX INC | $NVAX | MOTT DAVID M | Not found | M | Restricted Stock Units | 10420 | $0.00 | 0.0000 | 152,190,000 | 100.00% | 0.01% |
| June 9, 2025 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | P | Common Stock | 200000 | $3.69 | 2,696,871.0000 | 238,356,222 | 8.01% | 0.08% |
| May 15, 2025 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | P | Common Stock | 100000 | $3.29 | 2,496,871.0000 | 238,356,222 | 4.17% | 0.04% |
| May 2, 2025 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | P | Common Stock | 381377 | $4.22 | 2,396,871.0000 | 238,356,222 | 18.92% | 0.16% |
| Feb. 24, 2025 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | P | Common Stock | 77729 | $5.00 | 2,015,494.0000 | 238,356,222 | 4.01% | 0.03% |
| Jan. 21, 2025 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | P | Common Stock | 199000 | $4.99 | 1,937,765.0000 | 0 | 11.44% | 0.00% |
| Dec. 26, 2024 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | M | Stock Option (Right to Buy) | 100000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Dec. 26, 2024 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | M | Common Stock | 100000 | $0.55 | 1,738,765.0000 | 0 | 6.10% | 0.00% |
| Dec. 19, 2024 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | P | Common Stock | 213300 | $4.67 | 1,638,765.0000 | 0 | 14.96% | 0.00% |
| Nov. 13, 2024 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | P | Common Stock | 215868 | $4.62 | 1,425,465.0000 | 0 | 17.85% | 0.00% |
| July 1, 2024 | Adaptimmune Therapeutics PLC | $ADAPY | MOTT DAVID M | Director | A | Option to purchase Ordinary Shares | 1583214 | $0.00 | 1,583,214.0000 | 1,559,183,774 | 9999.99% | 0.10% |
| June 14, 2024 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | A | Common Stock | 17322 | $0.00 | 1,209,597.0000 | 0 | 1.45% | 0.00% |
| June 14, 2024 | ARDELYX, INC. | $ARDX | MOTT DAVID M | Director | A | Stock Option (Right to Buy) | 40243 | $0.00 | 40,243.0000 | 0 | 9999.99% | 0.00% |
| June 12, 2024 | NOVAVAX INC | $NVAX | MOTT DAVID M | Not found | A | Restricted Stock Units | 10420 | $0.00 | 10,420.0000 | 100,768,000 | 9999.99% | 0.01% |
| June 12, 2024 | NOVAVAX INC | $NVAX | MOTT DAVID M | Not found | M | Common Stock | 6670 | $0.00 | 50,470.0000 | 100,768,000 | 15.23% | 0.01% |
| June 12, 2024 | NOVAVAX INC | $NVAX | MOTT DAVID M | Not found | M | Restricted Stock Units | 6670 | $0.00 | 0.0000 | 100,768,000 | 100.00% | 0.01% |
| June 12, 2024 | NOVAVAX INC | $NVAX | MOTT DAVID M | Not found | A | Stock Option (Right to Buy) | 15630 | $15.86 | 15,630.0000 | 100,768,000 | 9999.99% | 0.02% |
| June 11, 2024 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | A | Stock Option (right to buy) | 55000 | $0.00 | 55,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 2, 2024 | Mersana Therapeutics, Inc. | $MRSN | MOTT DAVID M | Director | A | Common Stock | 8810 | $0.00 | 598,289.0000 | 0 | 1.49% | 0.00% |
| June 10, 2023 | NOVAVAX INC | $NVAX | MOTT DAVID M | Director | M | Common Stock | 3100 | $0.00 | 43,800.0000 | 78,183,000 | 7.62% | 0.00% |
| June 10, 2023 | NOVAVAX INC | $NVAX | MOTT DAVID M | Director | M | Restricted Stock Units | 3100 | $0.00 | 0.0000 | 78,183,000 | 100.00% | 0.00% |
| June 12, 2023 | NOVAVAX INC | $NVAX | MOTT DAVID M | Director | A | Stock Option (Right to Buy) | 7710 | $0.00 | 7,710.0000 | 78,183,000 | 9999.99% | 0.01% |
| June 12, 2023 | NOVAVAX INC | $NVAX | MOTT DAVID M | Director | A | Restricted Stock Units | 6670 | $0.00 | 6,670.0000 | 78,183,000 | 9999.99% | 0.01% |